A flexible blueprint for the future of drug development

The Lancet

Volumn 375, Issue 9712, 2010, Pages 357-359

  Barker, Richard ^a  

^a ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; BAYES THEOREM; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DRUG DEVELOPMENT; DRUG RESEARCH; PRESCRIPTION; PRIORITY JOURNAL;

EID: 75149130069     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60141-9     Document Type: Note

References (6)

1. Dimasi J.A. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther 69 (2001) 297-307
2. Innovative Medicines Initiative (IMI). http://imi.europa.eu/index_en.html (accessed Oct 25, 2009).
3. US Food and Drug Administration. Critical path initiative (Oct 13, 2009). http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/default.htm (accessed Oct 25, 2009).
4. Cooksey D. A review of UK health research funding (December, 2006). http://www.hm-treasury.gov.uk/d/pbr06_cooksey_final_report_636.pdf (accessed Oct 25, 2009).
5. Rawlins M. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet 372 (2008) 2152-2161
6. Berry D.A., Stangl D., and Berry B.A. Bayesian biostatistics (1996), Taylor & Francis, New York